Association between localised retinal nerve fibre layer defects and cardiovascular risk factors

Joo Youn Shin1,2, Jonghyun Lee1, Chan Joo Lee3,4, Sungha Park4 & Suk Ho Byeon2*

Localised retinal nerve fibre layer defects (RNFLDs) are reported to indicate the degree of glaucomatous damage but can also be sequelae of retinal vascular insufficiency as a result of systemic vascular factors. We investigated the association between RNFLDs and cardiovascular risk factors. RNFLDs were detected in 440 (29.2%) of 1508 subjects. The presence of RNFLDs was associated with higher HbA1c (odds ratio [OR] 1.289, \( p < 0.001 \)), higher 24-h mean systolic blood pressure (SBP; OR 1.013, \( p < 0.005 \)), and lower estimated glomerular filtration rate (eGFR; OR 0.995, \( p < 0.005 \)). An increasing number of RNFLDs was correlated with higher SBP (\( r = 0.186, p < 0.001 \)), higher HbA1c (\( r = 0.128, p < 0.010 \)), lower eGFR (\( r = -0.112, p < 0.020 \)), and younger age (\( r = -0.303, p < 0.001 \)). Subjects with RNFLDs had a higher predicted 10-year risk of atherosclerotic cardiovascular disease than did those without RNFLDs (9.7% vs 7.9%, \( p = 0.008 \) in middle-aged subjects, 25.6% vs 23.2%, \( p = 0.040 \) in older subjects). In conclusion, RNFLDs are associated with SBP, eGFR, and HbA1c. Concomitant cardiovascular risk factors should be considered when evaluating patients with localised RNFLDs.

Localised retinal nerve fibre layer defects (RNFLDs) have been reported to be a sensitive indicator of the degree of glaucomatous damage in patients with glaucomatous optic neuropathy1. However, these defects are not pathognomonic of glaucoma and can also be sequelae of retinal vascular insufficiency2. In an experiment in rhesus monkeys, chronic arterial hypertension and atherosclerosis were reported to lead to localised RNFLDs without glaucomatous changes in the neuroretinal rim or peripapillary atrophy3. Localised RNFLDs can also develop after appearance of retinal cotton-wool spots in patients with systemic hypertension or diabetes mellitus (DM)2,4.

Previous studies have suggested an association between localised RNFLDs and risk factors for cardiovascular disease, including high blood pressure (BP) and diabetes5,6. Localised RNFLDs have also been reported to be associated with cerebral small vessel disease and stroke7,8, suggesting that these lesions are potential biomarkers of cardiovascular risk. However, most of the studies performed to date have analysed a limited number of subjects or have not fully evaluated the various systemic factors.

The Cardiovascular and Metabolic Disease Etiology Research Center-High Risk Cohort (CMERC-HI) study is a prospective cohort investigation of the value of known and novel predictors of clinical outcomes in subjects at risk of cardiovascular disease. The aim of the present study was to evaluate the association between localised RNFLDs and various cardiovascular risk factors using the baseline CMERC-HI data to improve understanding of the pathogenesis of RNFLDs.

Results

Subject characteristics at baseline. Localised RNFLDs were detected in 440 (29.2%) of the 1508 subjects (Table 1). Subjects with RNFLDs had a higher glycated haemoglobin (HbA1c) level (\( p = 0.003 \)), higher BP (mean 24-h systolic BP [SBP] and diastolic BP [DBP], daytime SBP, night-time SBP and DBP [\( p < 0.001 \)], and day-time DBP [\( p = 0.007 \)]) and a lower estimated glomerular filtration rate (eGFR; \( p < 0.001 \)) than did those without RNFLDs. There was no difference in age (\( p = 0.131 \)), sex (\( p = 0.424 \)), rate of hypertension (\( p = 0.968 \)), rate of DM (\( p = 0.102 \)), lipid profile values, or urinary albumin to creatinine ratio between the two groups.

1Department of Ophthalmology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, South Korea. 2Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea. 3Department of Health Promotion, Severance Hospital, Seoul, Republic of Korea. 4Cardiology Division, Severance Cardiovascular Hospital and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. *email: shbyeon@yuhs.ac
Association between RNFLDs and cardiovascular risk factors. In the regression analysis, localised RNFLDs was the dependent variable and other parameters that were significantly associated with localised RNFLDs in the univariate analysis (Table 1) and were clinically significant were the independent variables. In the multivariate logistic regression, higher HbA1c (odds ratio [OR] 1.289, 95% confidence interval [CI] 1.13–1.47, \( p < 0.001 \)) or BMI (\( p = 0.001 \)), higher 24-h mean SBP (OR 1.013, 95% CI 1.004–1.022, \( p < 0.001 \)), and lower eGFR (OR 0.994, 95% CI 0.989–0.998, \( p = 0.005 \)) were found to be associated with the presence of localised RNFLDs.

Given the association of presence of localised RNFLDs with higher HbA1c, we performed regression analysis by dividing the subjects into a diabetes group and a non-diabetes group. In the non-diabetes group, the presence of localised RNFLDs was associated with a higher 24-h mean SBP (OR 1.013, 95% CI 1.004–1.022, \( p = 0.005 \)) and lower eGFR (OR 0.995, 95% CI 0.991–0.998, \( p = 0.005 \)) after adjustment for age, sex, and body mass index (BMI). In the diabetes group, the presence of RNFLDs was significantly associated with a higher HbA1c (OR 1.446, 95% CI 1.195–1.749, \( p < 0.001 \)) and a higher 24-h mean SBP (OR 1.014, 95% CI 1.004–1.028, \( p = 0.045 \)) after adjustment for age, sex, BMI, and eGFR (OR 0.994, 95% CI 0.988–1.00, \( p = 0.057 \), for eGFR).

Correlation between number of RNFLDs and cardiovascular risk factors. As with the presence of RNFLDs, the number of RNFLDs was significantly correlated with higher HbA1c (\( r = 0.128, p = 0.010 \)), higher mean 24-h SBP (\( r = 0.186, p < 0.001 \)), and lower eGFR (\( r = -0.112, p = 0.200 \)). The increasing number of RNFLDs was also correlated with younger age (\( r = -0.303, p < 0.001 \)). No correlation was detected between the number of RNFLDs and sex (\( p = 0.924 \)) or BMI (\( p = 0.972 \); Table 3).

Predicted 10-year risk of atherosclerotic cardiovascular disease. Six hundred and twenty-three subjects were aged 40–59 years (designated the middle-aged group) and 781 were aged 60–79 years (designated the older group). RNFLDs were observed in 31.5% of the middle-aged group and 26.9% of the older group. The mean ASCVD risk score for subjects with RNFLDs was 9.7% in the middle-aged group and 25.6% in the older group; the score was significantly higher in subjects with RNFLDs than in those without RNFLDs in both age groups (\( p = 0.008 \) and \( p = 0.040 \), respectively; Table 4).

### Table 1. Baseline characteristics according to the presence of localised retinal nerve fibre layer defects. The data are shown as the mean ± standard deviation or the number (percentage). *\( p < 0.05 \). ACR, albumin to creatinine ratio; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RNFLD, localised retinal nerve fibre layer defect; SBP, systolic blood pressure.
Discussion

The present study investigated the association between localised RNFLDs and cardiovascular risk factors and showed that RNFLDs were associated with 24-h mean SBP, HbA1c, and eGFR values after adjustment. An increasing number of RNFLDs was also correlated with higher SBP, lower eGFR, higher HbA1c, and younger age. The 10-year predicted risk of cardiovascular disease using the ASCVD score was significantly higher in subjects with localised RNFLDs than in those without RNFLDs. Our results suggest that concomitant cardiovascular risk factors should be considered when evaluating patients with localised RNFLDs.

Localised RNFLDs have been reported to be associated with arterial hypertension5,9,10. Chronic arterial hypertension and atherosclerosis led to development of localised RNFLDs in a rhesus monkey model 3, and localised RNFLDs were also reported to be associated with increasing grades of arterial hypertension5. The most common causes of RNFLDs in patients with uncontrolled hypertension are cotton-wool spots11 and/or hypertensive optic neuropathy12. The authors of a study in primates with experimental renovascular hypertension suggested that autoregulatory vasoconstriction in the superficial arterioles resulting from high BP leads to occlusive sequelae and ischemic damage in the inner retina5,13. Our finding of an association between localised RNFLDs and higher BP, i.e., the probability of having RNFLDs increases by 1.13-fold with a 10-mmHg increment in blood pressure, is in line with earlier reports.

Analysis of our 24-h ambulatory BP monitoring results revealed that the presence of RNFLDs was associated with persistently high SBP and DBP. It has been reported that ambulatory BP provides better prognostic information than does BP recorded in the office in patients with cardiovascular disease and that high BP at night increases the cardiovascular risk in patients with high ambulatory daytime BP14. Therefore, the finding in our study that both daytime and night-time BP values were higher in subjects with RNFLDs than in those without RNFLDs suggests an increased likelihood of cardiovascular events, as seen in previous studies that have identified an association between RNFLDs and stroke5,9.

Table 2. Factors associated with presence of localised retinal nerve fibre layer defects using multivariate logistic regression analysis. *p < 0.05. BMI, body mass index; CI, confidence interval; HbA1c, glycated haemoglobin; OR, odds ratio; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate.

| Variables                        | OR     | 95% CI             | P-value |
|----------------------------------|--------|--------------------|---------|
| Age (1-year increment)           | 0.991  | 0.98–1.002         | 0.110   |
| Sex (Female vs male)             | 0.950  | 0.74–1.23         | 0.695   |
| BMI (1-kg/m² increment)          | 0.974  | 0.94–1.01         | 0.144   |
| HbA1c (%) (1% increment)         | 1.289  | 1.13–1.47          | <0.001* |
| Mean 24-h SBP (1-mmHg increment) | 1.013  | 1.004–1.022       | 0.005*  |
| eGFR (1-mL/min/1.73 m² increment)| 0.995  | 0.991–0.998       | 0.005*  |

Table 3. Correlation between number of localised retinal nerve fibre layer defects and cardiovascular risk factors. *p < 0.05. RNFLD, retinal nerve fibre layer defect; BMI, body mass index; HbA1c, glycated haemoglobin; SBP, mean systolic blood pressure; eGFR, estimated glomerular filtration rate.

| Variables                              | RNFLDs, n | Pearson's coefficient | p-value |
|----------------------------------------|------------|-----------------------|---------|
| Age (years)                            | 61.8 ± 10.5| 51.3 ± 11.9          | −0.303  | <0.001* |
| Sex (M/F)                              | 125/92     | 84/57                 | 0.005   | 0.924   |
| BMI (1-kg/m² increment)                | 25.0 ± 3.3  | 25.0 ± 4.6           | 0.002   | 0.972   |
| Mean 24-h SBP (mmHg)                   | 131.5 ± 14.4| 139.5 ± 18.7        | 0.186   | <0.001* |
| HbA1c (%)                              | 6.10 ± 0.85| 6.45 ± 1.39         | 0.128   | 0.010   |
| eGFR (mL/min/1.73 m²)                  | 61.1 ± 34.0| 49.7 ± 35.5         | −0.112  | 0.020   |

Table 4. Predicted 10-year risk of ASCVD by ASCVD score according to the presence of localised retinal nerve fibre layer defects. *p < 0.05. RNFLD, retinal nerve fibre layer defect; ASCVD, atherosclerotic cardiovascular disease.

| Age group    | n   | 10-year risk predicted by ASCVD score (%) | p-value |
|--------------|-----|------------------------------------------|---------|
| 40–59 years  |     |                                         |         |
| RNFLD (−)    | 427 | 7.9 ± 7.1                                | 0.008*  |
| RNFLD (+)    | 196 | 9.7 ± 8.2                                |         |
| 60–79 years  |     |                                         |         |
| RNFLD (−)    | 571 | 23.2 ± 14.5                              | 0.040*  |
| RNFLD (+)    | 210 | 25.6 ± 14.6                              |         |
The presence of localised RNFLDs was also associated with the HbA1c value. Although the mechanism of RNFLDs in subjects with diabetes is not completely understood, oxidative stress, accumulation of advanced glycation end products, and impaired retrograde axonal transport of ganglion cells have been suggested to play a role\textsuperscript{2,15,16}. Acute nonperfusion of the retina causes a blockage of axoplasmic transport and formation of cotton-wool spots, and it has been reported that approximately 22% of cotton-wool spots cause clinically visible RNFLDs in patients with diabetic retinopathy\textsuperscript{2}. The frequency of these changes was reported to depend on the severity and duration of disease and on the BP\textsuperscript{17}. Increased BP has been hypothesised to damage the retinal capillary endothelial cells in patients with diabetes\textsuperscript{18}, and our finding that the presence of RNFLDs in subjects with diabetes was also associated with SBP after adjustment for HbA1c is consistent with the mechanism proposed in previous studies.

There was an independent association between the presence of RNFLDs and a lower eGFR, particularly in subjects without diabetes after adjustment for other cardiovascular risk factors. Pathogenic abnormalities, including dysfunction of the renin-angiotensin system, atherosclerosis, and oxidative stress, may occur throughout the body; microvascular damage from hypertension, DM, and other processes affecting the retinal and renal vasculature may be useful indicators of cumulative damage. Previous studies have shown that the RNFL is thinner in patients who have chronic renal failure without DM\textsuperscript{19} and in those receiving haemodialysis\textsuperscript{20} than in the normal population. The authors of those studies suggested subclinical ischemic retinopathy as the reason for the reduction in retinal thickness in patients with chronic kidney disease. Our result is consistent with their findings and suggests that localised RNFLDs could indicate generalised systemic microvascular injury and also reflect underlying renal injury\textsuperscript{21}.

As with the presence of RNFLDs, the number of RNFLDs was significantly correlated with cardiovascular risk factors including higher SBP, lower eGFR, and higher HbA1c, supporting the notion that RNFLDs could be a potential biomarker of cardiovascular risk\textsuperscript{22,23}. On the other hand, the number of RNFLDs inversely correlated with age. The reason for this result is unclear, but we can speculate about the reason on the basis of the finding in a previous study that younger age was a strong independent risk factor for development of grade III/IV hypertensive retinopathy\textsuperscript{23}. Alternatively, this finding could reflect the decreased visibility of localised RNFLDs in older individuals\textsuperscript{3}. Subjects with RNFLDs had a significantly higher predicted 10-year risk for ASCVD than did those without RNFLDs regardless of whether they were middle-aged or older. This result suggests that RNFLDs may have a predictive value with regard to cardiovascular risk. In particular, given our findings that the number of RNFLDs was inversely correlated with age and that the ASCVD risk score in the RNFLD group was more significant in the middle-aged group than in the older group, RNFLDs may be of more benefit for prediction of cardiovascular risk in younger, middle-aged individuals with risk factors. A longitudinal study will be needed to answer this question.

There are some limitations to our study. We included only subjects of the same ethnicity with a high risk of developing cardiovascular disease, so it may be difficult to generalise our findings. Similar studies in the general population are now needed. Furthermore, a previous study reported that the ASCVD risk score in the Korean population was overestimated by the ACC/AHA risk equations\textsuperscript{24}, so our calculated risk score may not reflect the actual risk. We anticipate that the 5–10-year outcomes in our cohort will be needed to determine conclusively whether or not evaluation of RNFLDs would be of benefit over and above that of existing methods for prediction of cardiovascular risk. The cross-sectional study design and lack of a control group were further limitations. There are some limitations to our study. We included only subjects of the same ethnicity with a high risk of developing cardiovascular disease, so it may be difficult to generalise our findings. Similar studies in the general population are now needed. Furthermore, a previous study reported that the ACC/AHA risk equations\textsuperscript{24}, so our calculated risk score may not reflect the actual risk. We anticipate that the 5–10-year outcomes in our cohort will be needed to determine conclusively whether or not evaluation of RNFLDs would be of benefit over and above that of existing methods for prediction of cardiovascular risk. The cross-sectional study design and lack of a control group were further limitations.

In conclusion, our findings indicate that localised RNFLDs are associated with certain cardiovascular risk factors, including SBP, eGFR, and HbA1c, suggesting that concomitant cardiovascular risk factors should be considered when evaluating a patient with localised RNFLDs.

**Methods**

**Study populations.** The Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, has been enrolling subjects in the CMERC-HI cohort study (ClinicalTrials.gov identifier NCT02003781) since December 2013. The study protocol will be reported in detail elsewhere. This study was performed in accordance with the tenets of the Declaration of Helsinki. The Institutional Review Board at Yonsei University approved the protocol for the present study (4-2014-000) and all participants provided written informed consent.

Subjects are deemed to have cardiovascular risk factors and enrolled in the CMERC-HI cohort study if they have any of the following: high-risk hypertension (eGFR > 60 mL/min/1.73 m\(^2\) with damage to at least one target organ or an eGFR > 60 mL/min/1.73 m\(^2\)); DM with albuminuria; anuric end-stage renal disease requiring dialysis; a relative who sustained an acute myocardial infarction when aged younger than 55 years (if male) or 65 years (if female); asymptomatic atherosclerotic disease (abdominal aorta diameter > 3 cm or ankle-brachial index > 0.9); carotid plaque or carotid intima-media thickness > 0.9 mm, an asymptomatic old cerebrovascular accident, or > 30% stenosis in at least one major coronary artery); rheumatoid arthritis, age > 40 years, and taking methotrexate and steroids; atrial fibrillation with a CHA2DS-VASc score ≥ 1; and a history of kidney transplantation more than 3 months beforehand. Subjects aged > 20 years who met at least one inclusion criterion were enrolled in our present study. We excluded subjects with any of the following: acute myocardial infarction, acute coronary syndrome, or symptomatic coronary artery disease, or a history of any of these diseases; symptomatic peripheral artery disease or heart failure, or a history of either of these diseases; expected survival of less than 6 months for
In this study, we analysed the baseline data for 1508 subjects enrolled in the CMERC-HI cohort between November 2013 and June 2016 who agreed to an examination of the fundus.

Assessment of cardiovascular risk factors. Subjects underwent a standardised interview that included questions about a known diagnosis of hypertension, DM, and chronic kidney disease, as well as the current treatment of these diseases. Anthropometric parameters, including body height and weight, were measured. The HbA1c level and blood glucose, lipid, blood urea nitrogen, creatinine, and urinary albumin concentrations were measured in blood samples taken after fasting overnight and spot urine specimens. SBP and DBP were measured at 30-min intervals while subjects performed their normal daily activities, including sleep, using a 24-h ambulatory BP monitor (TM-2430, A & D Medical, Tokyo, Japan).

Predicted 10-year risk for atherosclerotic cardiovascular disease. ASCVD is defined as a non-fatal myocardial infarction (heart attack), death from coronary heart disease, or stroke. The American College of Cardiology/American Heart Association (ACC/AHA) 2013 Pooled Cohort Equations formula estimates the 10-year risk of ASCVD in patients who have never experienced one of these events in the past based on the covariates of age, treated or untreated systolic BP level, total cholesterol and high-density lipoprotein cholesterol levels, current smoking status (yes/no), and history of diabetes (yes/no). Using this formula, the ASCVD risk score was calculated and compared between subjects with and without RNFLDs. One hundred and four of 1508 subjects were excluded from the analysis for being aged younger than 40 years or older than 80 years (ASCVD risk score not applicable; n = 94) or having a total cholesterol level < 100 despite being within the appropriate age range (n = 10).

Retinal imaging with fundus photography and spectral-domain OCT. All subjects underwent fundus photography and spectral-domain optical coherence tomography (OCT) on the same day. For both examinations, the pupils were dilated using tropicamide 1%. Two fundus photographs of each eye, the first centred on the optic disc and the second centred on the fovea, were acquired using a 45° fundus camera (Visucam 500/765, Carl Zeiss Meditec, Jena, Germany). Spectral-domain OCT (Spectralis HRA HR OCT; Heidelberg Engineering GmbH, Dossenheim, Germany) was used to obtain circular scans (3.4 mm in diameter) centred at the optic disc and horizontal, vertical, B, and volume scans of the macular area. The volume scans contained 49 sections (with spacing of 120 μm) of a 20 × 20° area of the macula. Bilateral fundus photographs and OCT images were available for 1503 of the 1508 subjects (5 subjects underwent examination of the fundus of only one eye because of media opacity).

A localised RNFLD was defined as a dark wedge-shaped area with a connecting optic disc border on fundus photography that had a width or length of 5°–45°, which was confirmed on OCT as an abruptly dropped contour line on the RNFL thickness profile (Fig. 1). The images of the fundus were assessed by an ophthalmologist (JYS) who was blinded to all subject data except for the fundus photographs and OCT images. To determine the inter-observer variability, photographs of 100 randomly selected subjects were reviewed by two blinded ophthalmologists (JYS, SHB) working independently of each other. The coefficient for inter-observer variability in detection of localised RNFLDs was 0.99. RNFLDs associated with significant glaucomatous changes at the optic disc, chorioretinal scarring, a history of uveitis, or retinal artery or vein occlusion were not regarded as localised RNFLDs in the analysis.
**Statistical analysis.** The independent t-test was used for continuous variables and the chi-squared test for categorical variables when comparing the baseline characteristics of the subject groups with and without RNFLDs. Multivariate logistic regression was used to determine the association between presence of RNFLDs and cardiovascular risk factors. ORs and 95% CIs were calculated. In multivariate logistic regression, we used the presence of RNFLDs as a dependent variable. Parameters that were significantly associated with RNFLDs in the univariate analysis and were clinically significant were used as independent variables. Therefore, subjects with higher values for one or more independent variables (e.g., systolic pressure) had higher odds of having RNFLDs. In subjects with RNFLDs, the number of RNFLDs was regarded as the number of RNFLDs in the eyes with more RNFLDs. The Pearson correlation test was performed to determine the correlation between the number of RNFLDs and cardiovascular risk factors. The ASCVD risk score was compared between the groups with and without RNFLDs using the independent t-test. Given that age had a strong influence on the ASCVD risk score, we divided the subjects into groups aged 40–59 years (the middle-aged group) and those aged 60–79 years (older group). The statistical analysis was performed using SPSS for Windows (version 21.0; IBM Corp., Armonk, NY). A p-value < 0.05 was considered statistically significant.

**Data availability**
All data generated or analysed during this study are included in this article.

Received: 18 February 2019; Accepted: 14 August 2019;
Published online: 18 December 2019

**References**

1. Jonas, J. B. & Schiro, D. Localised wedge shaped defects of the retinal nerve fibre layer in glaucoma. *Br. J. Ophthalmol.* 78, 285–290 (1994).
2. Chihara, E., Matsuoka, T., Ogura, Y. & Matsumura, M. Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. *Ophthalmology* 100, 1147–1151 (1993).
3. Hayreh, S. S. & Jonas, J. B. Appearance of the optic disk and retinal nerve fiber layer in atherosclerosis and arterial hypertension: an experimental study in rhesus monkeys. *Am. J. Ophthalmol.* 130, 91–96 (2000).
4. Alencar, L. M., Medeiros, F. A. & Weinreb, R. Progressive Localized Retinal Nerve Fiber Loss Following a Retinal Cotton Wool Spot. *Semin. Ophthalmol.* 22, 103–104 (2007).
5. Xu, L. et al. Localized retinal nerve fiber layer defects and arterial hypertension. *Am. J. Hypertens.* 26, 511–517 (2013).
6. Je, R. et al. Ten-Year Incidence of Retinal Nerve Fiber Layer Defects: The Beijing Eye Study 2001/2011. *Invest. Ophthalmol. Vis. Sci.* 56, 5118–5124 (2015).
7. Kim, M. et al. Retinal nerve fiber layer defect and cerebral small vessel disease. *Invest. Ophthalmol. Vis. Sci.* 52, 6882–6886 (2011).
8. Wang, D. et al. Localized retinal nerve fiber layer defects and stroke. *Stroke* 45, 1651–1656 (2014).
9. Jonas, J. B. & Schiro, D. Localized retinal nerve fiber layer defects in nonglaucomatous optic nerve atrophy. *Graefes Arch. Clin. Exp. Ophthalmol.* 232, 759–760 (1994).
10. Zhang, Y. et al. Ophthalmoscopic Assessment of the Retinal Nerve Fiber Layer. The Beijing Eye Study. *PLoS ONE* 8 (2013).
11. Hayreh, S. S., Servais, G. E. & Virdi, P. S. Cotton-wool spots (inner retinal ischemic spots) in malignant arterial hypertension. *Ophthalmologica* 198, 215–219 (1985).
12. Hayreh, S. S., Servais, G. E. & Virdi, P. S. Fundus lesions in malignant hypertension. V. Hypertensive optic neuropathy. *Invest. Ophthalmol.* 93, 74–87 (1986).
13. McLeod, D., Marshall, J., Kohnen, E. M. & Bird, A. C. The role of axoplasmic transport in the pathogenesis of retinal-cotton-wool spots. *Br. J. Ophthalmol.* 61, 177–191 (1977).
14. Hansen, T. W., Jeppesen, J., Rasmussen, S., Ibsen, H. & Torp-Pedersen, C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. *Am. J. Hypertens.* 19, 243–250 (2006).
15. Amano, S. et al. Advanced glycation end products in human optic nerve head. *Br. J. Ophthalmol.* 85, 52–55 (2001).
16. Zhang, L. et al. Retrograde axonal transport impairment of large- and medium-sized retinal ganglion cells in diabetic rat. *Curr Eye Res.* 20, 131–136 (2000).
17. Schmidt, D. The mystery of cotton-wool spots - a review of recent and historical descriptions. *Eur. J. Med. Res.* 13, 231–266 (2008).
18. Kohnen, E. M. Diabetic retinopathy. *Br. Med. Bull.* 45, 148–173 (1989).
19. Demir, M. N. et al. Retinal nerve fiber layer thickness in chronic renal failure without diabetes mellitus. *Eur. J. Ophthalmol.* 19, 1034–1038 (2009).
20. Atilgan, C. U. et al. Effects of hemodialysis on macular and retinal nerve fiber layer thicknesses in non-diabetic patients with end stage renal failure. *Saudi Med. J.* 37, 641–647 (2016).
21. Balmforth, C. et al. Choriotireal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. *JCI Insight* 1, 89173; https://doi.org/10.1172/jci.insight.89173 (2016).
22. Jung, K. L., Kim, S. J. & Park, C. K. Systemic Vascular Risk Factors for Multiple Retinal Nerve Fiber Layer Defects. *Sci. Rep.* 8, 7797 (2018).
23. Henderson, A. D. et al. Grade III or Grade IV Hypertensive Retinopathy with Severely Elevated Blood Pressure. *West. J. Emerg. Med.* 13, 529–534 (2012).
24. Jung, K. J. et al. The ACC/AHA 2013 pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic cardiovascular disease. *Atherosclerosis* 242, 367–373 (2015).
25. Goff David, C. et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. *Circulation* 129, S49–S73 (2014).
26. Lee, J., Kim, J. & Kee, C. Characteristics of patients with a localized retinal nerve fiber layer defect and normal optic disc appearance. *Eye* 26, 1473–1478 (2012).

**Acknowledgements**
This research was supported by the Korea Health Technology R & D Project through the Korea Health Industry Development Institute funded by the Ministry of Health and Welfare, Republic of Korea (grants HI13C0715 and HI17C1567). The authors declare that no competing interests exist with the funder. The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript. The authors would like to thank Professor Hyoung Won Bae (Department of Ophthalmology, Yonsei University College of Medicine) for evaluating the glaucoma data.
Author contributions
Design and conduct of the study: J.Y.S., C.J.L., S.P. and S.H.B. Collection, management, analysis, and interpretation of the data: J.Y.S., C.J.L., J.L., S.P. and S.H.B. Preparation, review, or approval of the manuscript: J.Y.S., C.J.L., J.L., S.P. and S.H.B. Decision to submit the manuscript for publication: J.Y.S., C.J.L., J.L., S.P. and S.H.B.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to S.H. .

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2019